Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation (IMCL) ... medicine, treatment of infectious diseases as well as ... and prevention of pathologies like cardiovascular disease, Alzheimer,s ... 2014, ImmunoClin Corporation will complete the strategic relocation ... D.C. , a key center of North ...
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... South Carolina (PRWEB) July 29, 2014 DisasterTalk ... teams of people where cell phone masts or other transmitters ... up to 100 feet away without the need for any ... target longer ranges. , The new app has launched as ... US homes are at very high risk of being affected ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2
... ... additional stability storage space, additional retain sample storage, and a controlled environment room. ... Wilson, NC (PRWEB) ... and short term storage of stability samples, sample management, and logistics for the Biotechnology, ...
... REGENSBURG, Germany, June 17 , ... the Field of Reproductive Medicine , - ... Exhibition in,Amsterdam (Stand 87/88) , The IT ... its new software for in vitro fertilisation, MedITEX IVF,at the 25th ...
... Advanced Cell Technology,s Chief Scientist, Robert Lanza yields answers to ... MSNBC.com featured today Dr. Robert Lanza,s book (co-authored with ... are the Keys to Understanding the True Nature of the ... The article by Science Editor Alan Boyle includes an ...
Cached Biology Technology:Precision Stability Storage Announces Upcoming Expansion 2Precision Stability Storage Announces Upcoming Expansion 3New IVF Software MedITEX to be Presented at the ESHRE Exhibition 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 3
(Date:7/29/2014)... territory of Ascension Island, one of the world,s largest ... , Writing in the journal Biodiversity and Conservation ... Island Government Conservation Department report that the number of ... has increased by more than 500 per cent since ... nests are now estimated to be laid on the ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
(Date:7/29/2014)... 1 in 100,000 people characterized by a loss of ... unknown, a new study by a team of researchers at ... and other European institutions confirms for the first time that ... July in Nature Genetics , is an important step ... sphincter in the lower esophagus opens, allowing food to enter ...
Breaking Biology News(10 mins):Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2Mysterious esophagus disease is autoimmune after all 2
... apparently had genomes no larger than that of a modern ... genome size among living species and then used that new ... extinct dinosaurs and birds, whose bone cells can be measured ... University and the University of Reading, were led by Chris ...
... mutations that give rise to a rare genetic disease, ... may have a broader role during human development, potentially ... An international team of researchers identified two genes that ... disease that affects an estimated one in 10,000 children. ...
... mutation in mice results in an enhanced long-term memory, ... the journal Cell, published by Cell Press. These findings ... a drug to treat memory loss, according to the ... increases levels of a natural memory-blocking protein. Animals that ...
Cached Biology News:Despite their heft, many dinosaurs had surprisingly tiny genomes 2Gene found for rare disorder may reveal new pathway in mental retardation 2Mutation improves memory, may lead to memory-enhancing pill 2Mutation improves memory, may lead to memory-enhancing pill 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Request Info...
Biology Products: